SYSTEMIC ADMINISTRATION OF CELLULAR INTERLEUKIN-10 CAN EXACERBATE CARDIAC ALLOGRAFT REJECTION IN MICE1,2

Publisher Website
Google Scholar
Abstract
Cellular interleukin-10 (cIL-10) has been shown to inhibit cytokine production by T helper type 1 (Th1) cells by blocking antigen presenting cell function. This activity has suggested that IL-10 might be useful in the treatment of transplant rejection. Stimulatory effects of IL-10 however, have also been observed both on T and B cell differentiation. In this study, we examined the influence of recombinant (r) mouse (m) IL-10 on heterotopic vascularized heart allograft survival in the B10(H2b)→C3H(H2k) strain combination that crosses both major histocompatibility complex (MHC) and non-MHC-histocompatibility antigen(non-MHC-HA) barriers. The influence of IL-10 was also examined in the B10.BR(H2k)→C3H combination with disparity at only non-MHC-HA loci. Postoperative intraperitoneal administration of IL-10 (100 μg/d, days 0-6) significantly accelerated heart graft rejection both in the B10→C3H (mean survival time [MST] 7.8±0.2 days; control MST 10.6±0.6 days;P.

This publication has 27 references indexed in Scilit: